"This issuance strengthens our growing IP portfolio in our brain cancer treatment using Pritumumab, a unique natural antibody that crosses the blood brain barrier," said Sean Carrick, CEO of Nascent. "As we conclude our Phase I trial, this patent enhances our milestone achievements of moving the asset forward."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.